(Photo by Flickr user Luca Volpi, used under a Creative Commons license)
Personal Genome Diagnostics (PGDx) received a new contract from the U.S. Department of Veterans Affairs to provide a test for cancer that does not require tissue samples.
The Canton-based company makes a liquid biopsy, which tests for cancer by evaluating 64 genes that are associated with cancer.
The test can be conducted through a blood test, rather than obtaining tissue samples through a traditional biopsy or conducting an ultrasound. The test can also be conducted multiple times during treatment, providing a “real-time livestream of what’s happening at the genetic level in the patient’s tumor or tumors,” PGDx Manager for Translational Science and Diagnostics John Simmons told Technical.ly last year.
The test will be offered to advanced cancer patients who are receiving treatment in the VA, according to the company.
The company’s work on liquid biopsy got attention from the White House last year, when Vice President Joe Biden included PGDx among the group of experts working on the Cancer Moonshot.
The new contract is an expansion of work with the VA for PGDx, which was founded by Johns Hopkins researchers. PGDx also has a contract to provide its product which analyzes tumors on the genetic level.
The company raised a $21.4 million Series A in 2015.-30-
University of Maryland awarded $200M for flu vaccine research
MICA Game Lab and Shock Trauma are developing VR games for spinal injury patients
Fearless wins federal funding to develop platform for Air Force mobile developers
Why two eminent Baltimore higher-ed institutions collaborated to create this unique dual degree program
BurnAlong adds digital connection to the local American Heart Association’s CycleNation event
DreamPort plans expansion of Columbia collaboration space
Johns Hopkins, Eastern Shore Entrepreneurship Center win federal grant funding
What Asymmetrik is doing to help lead healthcare’s digital transformation
Sign-up for daily news updates from Technical.ly Baltimore